Obesity

Biotech firm says much of the world will be on obesity drugs in 50 years

Ozempic and Wegovy are just the beginning. The weight-loss drug sector is set to get more crowded and sophisticated.
EDITORIAL

Ozempic’s contradictory math has a simple answer